Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
November 07 2018 - 4:02PM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage
biopharmaceutical company, today announced that Dr. Simon Pimstone,
Xenon's Chief Executive Officer, will present a corporate update at
the Stifel 2018 Healthcare Conference in New York, NY on Tuesday,
November 13, 2018 at 9:30 am ET.
A live audio webcast of the presentation will be
available on the investors section of Xenon's website at
www.xenon-pharma.com and will be available for replay following the
event.
About Xenon Pharmaceuticals
Inc.
We are a clinical stage, neurology-focused
biopharmaceutical company focused on developing innovative
therapeutics to improve the lives of patients with neurological
disorders. Building upon our extensive knowledge of human genetics
and diseases caused by mutations in ion channels, known as
channelopathies, we are advancing – both independently and with our
collaborators – a novel product pipeline of central nervous system,
or CNS, therapies to address areas of high unmet medical need, such
as epilepsy, migraine and pain. For more information, please visit
www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered
trademarks or trademarks of Xenon Pharmaceuticals Inc. in various
jurisdictions. All other trademarks belong to their respective
owner.
Investor/Media Contact:Jodi
Regts Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email:
investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Sep 2023 to Sep 2024